Adenovirus type-5 vector-based Ebola vaccine was safe and immunogenic in healthy adults

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Background

A recombinant adenovirus type-5 vector-based vaccine expressing the glycoprotein of Ebola Zaire Makona variant showed good safety and immunogenicity in a phase 1 trial of healthy Chinese adults. We aimed to assess the safety and immunogenicity of this vaccine in healthy adults in ...